{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:07:24Z","timestamp":1791976044775,"version":"4.4.0"},"reference-count":0,"publisher":"American Diabetes Association","issue":"5","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[1997,5,1]]},"abstract":"<jats:p>Glucagon-like peptide I (GLP-I), an intestine-derived incretin hormone, is a potent stimulator of insulin and somatostatin secretion. In some studies, GLP-I is an inhibitor of glucagon secretion. It remains uncertain, however, whether the effect of GLP-I on the inhibition of glucagon secretion is direct, owing to interactions with GLP-I receptors on \u30b1-cells, or indirect, via paracrine suppression by insulin or somatostatin. The localization of the GLP-I receptor on insulin and somatostatin-producing cells in the islets is well established. Whether the GLP-I receptor also resides on the glucagon-producing \u03b1-cells remains controversial and is reported to be absent on rat \u03b1-cells. To investigate the distribution of the GLP-I receptor on islet cells, we examined the expression of GLP-I receptor mRNA in phenotypically distinct islet cell lines and islets, and the presence of immunoreactive GLP-I receptor in dispersed rat islet cells using a specific antiserum. GLP-I receptor mRNA was readily detected by reverse transcription\u2013polymerase chain reaction (RT-PCR) in both rat islets and in established islet cell lines representing distinct \u03b1-, \u03b2, and \u03b4-cell phenotypes. In addition, GLP I receptor expression was detected in single rat \u03b1-cells by single-cell RT-PCR. In dispersed rat islet cells analyzed by double immunofluorescent staining, 90% of the insulin, 76% of the somatostatin, and 20% of the glucagon positive cells colocalized with the GLP-I receptor immunoreactivity. Thus, a substantial population of glucagon immunoreactive \u03b1-cells express the GLP-I receptor. These findings imply that GLP-I may have a direct receptor-mediated action in the regulation of the physiological functions on a substantial subpopulation of \u03b1-cells. We suggest that a possible role for GLP-I receptors on \u03b1-cells may be to provide positive autocrine feedback control on glucagon secretion during fasting and\/or to dampen the potent paracrine suppression of glucagon secretion by insulin during feeding.<\/jats:p>","DOI":"10.2337\/diab.46.5.785","type":"journal-article","created":{"date-parts":[[2013,9,19]],"date-time":"2013-09-19T17:42:54Z","timestamp":1379612574000},"page":"785-791","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":107,"title":["Insulinotropic Glucagon-Like Peptide I Receptor Expression in Glucagon-Producing \u03b1-Cells of the Rat Endocrine Pancreas"],"prefix":"10.2337","volume":"46","author":[{"given":"R Scott","family":"Heller","sequence":"first","affiliation":[{"name":"Laboratory of Molecular Endocrinology, Massachusetts General Hospital, Howard Hughes Medical Institute, Harvard Medical School\u2008Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J","family":"Kieffer","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Endocrinology, Massachusetts General Hospital, Howard Hughes Medical Institute, Harvard Medical School\u2008Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel F","family":"Habener","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Endocrinology, Massachusetts General Hospital, Howard Hughes Medical Institute, Harvard Medical School\u2008Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/46\/5\/785\/363547\/46-5-785.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/46\/5\/785\/363547\/46-5-785.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T16:33:20Z","timestamp":1667406800000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/46\/5\/785\/9961\/Insulinotropic-Glucagon-Like-Peptide-I-Receptor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,5,1]]},"references-count":0,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1997,5,1]]}},"URL":"https:\/\/doi.org\/10.2337\/diab.46.5.785","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,5,1]]}}}